PDE6C and achromatopsia: These data indicate an overall gain of PDE6C function due to the high percentage of clones with the corrected pathogenic variant, both in homo- and heterozygosis, and highlight the use of CRISPR/Cas9 technology as a potential tool for the treatment of ACHM.